Peter Schmid-Grendelmeier
University Hospital Zurich, Dept. Dermatology · University of Zurich · University Hospital Zurich, Division of Dermatology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Schmid-Grendelmeier as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:26 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT05960266 · Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control StudyUniversity of Zurich · completed · Hypersensitivity, Hay Fever, Rhinitis, Allergic, Seasonal · principal investigator
- Ph2/Ph3NCT05378698 · Effects of Tralokinumab in the Skin: an Immunologic and Molecular InvestigationUniversity of Zurich · terminated · Atopic Dermatitis · principal investigator
- Ph2NCT01635127 · Efficacy Study of Canakinumab to Treat UrticariaUniversity of Zurich · unknown · Chronic Idiopathic Urticaria · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:26 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.N Engl J Med · 2010447 citationsRCR 13.8
- Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients.Transplantation · 2004121 citationsRCR 3.9
- Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study.J Allergy Clin Immunol Pract · 202124 citationsRCR 2.0
- Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).Dermatology · 202022 citationsRCR 1.4
- A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.Curr Med Res Opin · 200618 citationsRCR 0.7
- Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort.Dermatology · 200614 citationsRCR 0.6
- Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs.Swiss Med Wkly · 200613 citationsRCR 0.5
- Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.Allergy · 20249 citationsRCR 1.2
- Asthma rehabilitation at high vs. low altitude and its impact on exhaled nitric oxide and sensitization patterns: Randomized parallel-group trial.Respir Med · 20206 citationsRCR 0.4